Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 85Glioblastoma 82Pancreatic Neoplasms 75Glioma 65Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 54Colorectal Neoplasms 54Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 50Squamous Cell Carcinoma of Head and Neck 46Recurrence 46Ovarian Neoplasms 45Lymphoma 39Lymphoma, Non-Hodgkin 37Lymphoma, B-Cell 36Sarcoma 35Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 33Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Advanced Refractory Solid Tumors × Clear all
NCT03863145 2024-02-07

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Cosmo Pharmaceuticals NV

Phase EARLY_PHASE1 Recruiting
90 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡